Pharmacological blockade of KV1.3 channel as a promising treatment in autoimmune diseases

Invernizzi, 2010, Definition of human autoimmunity--autoantibodies versus autoimmune disease, Autoimmun. Rev., 9, A259, 10.1016/j.autrev.2009.12.002 Angum, 2020, The prevalence of autoimmune disorders in women: a narrative review, Cureus, 12 Rosenblum, 2015, Mechanisms of human autoimmunity, J. Clin. Invest., 125, 2228, 10.1172/JCI78088 Castiblanco, 2013, What is next after the genes for autoimmunity?, BMC Med., 11, 197, 10.1186/1741-7015-11-197 Feske, 2015, Ion channels in innate and adaptive immunity, Annu. Rev. Immunol., 33, 291, 10.1146/annurev-immunol-032414-112212 Cahalan, 2009, The functional network of ion channels in T lymphocytes, Immunol. Rev., 231, 59, 10.1111/j.1600-065X.2009.00816.x Wulff, 2007, Targeting effector memory T-cells with Kv1.3 blockers, Curr. Opin. Drug Discov. Dev, 10, 438 Veytia-Bucheli, 2018, Kv1.3 channel blockade with the Vm24 scorpion toxin attenuates the CD4+ effector memory T cell response to TCR stimulation, Cell Commun. Signal.: CCS, 16, 45, 10.1186/s12964-018-0257-7 Beeton, 2006, Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases, Proc. Natl. Acad. Sci. U. S. A, 103, 17414, 10.1073/pnas.0605136103 Tarcha, 2017, Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: a randomized phase 1b trial, PLoS One, 12, 10.1371/journal.pone.0180762 Hille, 1989, The Sharpey-Schafer Lecture. Ionic channels: evolutionary origins and modern roles, Q. J. Exp. Physiol., 74, 785, 10.1113/expphysiol.1989.sp003349 Martinac, 2008, Ion channels in microbes, Physiol. Rev., 88, 1449, 10.1152/physrev.00005.2008 Moran, 2015, Evolution of voltage-gated ion channels at the emergence of Metazoa, J. Exp. Biol., 218, 515, 10.1242/jeb.110270 Shen, 1995, Molecular recognition and assembly sequences involved in the subfamily-specific assembly of voltage-gated K+ channel subunit proteins, Neuron, 14, 625, 10.1016/0896-6273(95)90319-4 Murata, 2005, Phosphoinositide phosphatase activity coupled to an intrinsic voltage sensor, Nature, 435, 1239, 10.1038/nature03650 Ramsey, 2006, A voltage-gated proton-selective channel lacking the pore domain, Nature, 440, 1213, 10.1038/nature04700 Li, 1992, Specification of subunit assembly by the hydrophilic amino-terminal domain of the Shaker potassium channel, Science (New York, N.Y.), 257, 1225, 10.1126/science.1519059 Heinemann, 1996, Functional characterization of Kv channel beta-subunits from rat brain, J. Physiol., 493, 625, 10.1113/jphysiol.1996.sp021409 Hoshi, 1990, Biophysical and molecular mechanisms of Shaker potassium channel inactivation, Science (New York, N.Y.), 250, 533, 10.1126/science.2122519 Cuello, 2010, Structural mechanism of C-type inactivation in K(+) channels, Nature, 466, 203, 10.1038/nature09153 Misonou, 2004, Determinants of voltage-gated potassium channel surface expression and localization in Mammalian neurons, Crit. Rev. Biochem. Mol. Biol., 39, 125, 10.1080/10409230490475417 Roberds, 1991, Cloning and tissue-specific expression of five voltage-gated potassium channel cDNAs expressed in rat heart, Proc. Natl. Acad. Sci. U. S. A, 88, 1798, 10.1073/pnas.88.5.1798 Cahalan, 1985, A voltage-gated potassium channel in human T lymphocytes, J. Physiol., 358, 197, 10.1113/jphysiol.1985.sp015548 Plattner, 2014, Calcium regulation in the protozoan model, Paramecium tetraurelia, J. Eukaryot. Microbiol., 61, 95, 10.1111/jeu.12070 Plattner, 2013, Ca2+ signalling early in evolution--all but primitive, J. Cell Sci., 126, 2141 Dudev, 2014, Evolution of eukaryotic ion channels: principles underlying the conversion of Ca2⁺-selective to Na⁺-selective channels, J. Am. Chem. Soc., 136, 3553, 10.1021/ja4121132 Liebeskind, 2011, Evolution of sodium channels predates the origin of nervous systems in animals, Proc. Natl. Acad. Sci. U. S. A, 108, 9154, 10.1073/pnas.1106363108 Heinemann, 1992, Calcium channel characteristics conferred on the sodium channel by single mutations, Nature, 356, 441, 10.1038/356441a0 Chopra, 2007, Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: implications for the evolution of electrical signaling in vertebrates, BMC Evol. Biol., 7, 113, 10.1186/1471-2148-7-113 Feske, 2015, Ion channels in innate and adaptive immunity, Annu. Rev. Immunol., 33, 291, 10.1146/annurev-immunol-032414-112212 Brutkiewicz, 2016, Cell signaling pathways that regulate antigen presentation, J. Immunol. (Baltimore, Md, 197, 2971, 10.4049/jimmunol.1600460 Arthur, 2013, Mitogen-activated protein kinases in innate immunity, Nat. Rev. Immunol., 13, 679, 10.1038/nri3495 Yu, 2004, J. Immunol. (Baltimore, Md, 172, 6047, 10.4049/jimmunol.172.10.6047 Perez-Villar, 1999, Regulated association between the tyrosine kinase Emt/Itk/Tsk and phospholipase-C gamma 1 in human T lymphocytes, J. Immunol. (Baltimore, Md. : 1950, 163, 6435, 10.4049/jimmunol.163.12.6435 Prakriya, 2015, Store-operated calcium channels, Physiol. Rev., 95, 1383, 10.1152/physrev.00020.2014 Qi, 2007, Keeping the (kinase) party going: SLP-76 and ITK dance to the beat, Sci. STKE : Signal Transduct. Knowl. Environ., pe39 Vaeth, 2020, CRAC channels and calcium signaling in T cell-mediated immunity, Trends Immunol., 41, 878, 10.1016/j.it.2020.06.012 Zhang, 2005, STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane, Nature, 437, 902, 10.1038/nature04147 Vaeth, 2018, NFAT control of immune function, New Front. Abid. Trooper. F1000Res., 7, 260, 10.12688/f1000research.13426.1 Cahalan, 2009, The functional network of ion channels in T lymphocytes, Immunol. Rev., 231, 59, 10.1111/j.1600-065X.2009.00816.x Ledderose, 2020, The purinergic receptor P2Y11 choreographs the polarization, mitochondrial metabolism, and migration of T lymphocytes, Sci. Signal., 13, 10.1126/scisignal.aba3300 Schenk, 2011, ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors, Sci. Signal., 4, ra12, 10.1126/scisignal.2001270 Jin, 2008, Deletion of Trpm7 disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis, Science (New York, N.Y.), 322, 756, 10.1126/science.1163493 Patocka, 2021, Cyclosporine A: chemistry and toxicity - a review, Curr. Med. Chem., 28, 3925, 10.2174/0929867327666201006153202 Zhang, 2015, Discovery and structural optimization of 1-phenyl-3-(1-phenylethyl)urea derivatives as novel inhibitors of CRAC channel, Acta Pharmacol. Sin., 36, 1137, 10.1038/aps.2015.52 Chung, 1994, Inhibition by SK&F 96365 of Ca2+ current, IL-2 production and activation in T lymphocytes, Br. J. Pharmacol., 113, 861, 10.1111/j.1476-5381.1994.tb17072.x Maruyama, 1997, 2APB, 2-aminoethoxydiphenyl borate, a membrane-penetrable modulator of Ins(1,4,5)P3-induced Ca2+ release, J. Biochem., 122, 498, 10.1093/oxfordjournals.jbchem.a021780 Prakriya, 2001, Potentiation and inhibition of Ca(2+) release-activated Ca(2+) channels by 2-aminoethyldiphenyl borate (2-APB) occurs independently of IP(3) receptors, J. Physiol., 536, 3, 10.1111/j.1469-7793.2001.t01-1-00003.x Ishikawa, 2003, A pyrazole derivative, YM-58483, potently inhibits store-operated sustained Ca2+ influx and IL-2 production in T lymphocytes, J. Immunol. (Baltimore, Md, 170, 4441, 10.4049/jimmunol.170.9.4441 Zitt, 2004, Potent inhibition of Ca2+ release-activated Ca2+ channels and T-lymphocyte activation by the pyrazole derivative BTP2, J. Biol. Chem., 279, 12427, 10.1074/jbc.M309297200 Chen, 2013, Characterization of a novel CRAC inhibitor that potently blocks human T cell activation and effector functions, Mol. Immunol., 54, 355, 10.1016/j.molimm.2012.12.011 Sadaghiani, 2014, Identification of Orai1 channel inhibitors by using minimal functional domains to screen small molecule microarrays, Chem. Biol., 21, 1278, 10.1016/j.chembiol.2014.08.016 Pevarello, 2014, Ca(2+) release-activated Ca(2+) channel inhibitors, Pharma. Patent Anal., 3, 171, 10.4155/ppa.14.7 Wang, 2010, 105 Lin, 2013, Generation and characterization of fully human monoclonal antibodies against human Orai1 for autoimmune disease, J. Pharmacol. Exp. Therapeut., 345, 225, 10.1124/jpet.112.202788 Aki, 2020, Anti-ORAI1 antibody DS-2741a, a specific CRAC channel blocker, shows ideal therapeutic profiles for allergic disease via suppression of aberrant T-cell and mast cell activation, FASEB bioAdv., 2, 478, 10.1096/fba.2020-00008 Cox, 2013, Antibody-mediated targeting of the Orai1 calcium channel inhibits T cell function, PLoS One, 8, 10.1371/journal.pone.0082944 Wulff, 2003, The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS, J. Clin. Invest., 111, 1703, 10.1172/JCI16921 Beeton, 2005, Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases, Mol. Pharmacol., 67, 1369, 10.1124/mol.104.008193 Chiang, 2017, Potassium channels Kv1.3 and KCa3.1 cooperatively and compensatorily regulate antigen-specific memory T cell functions, Nat. Commun., 8, 14644, 10.1038/ncomms14644 Land, 2017, Kv1.3 channel blockade modulates the effector function of B cells in granulomatosis with polyangiitis, Front. Immunol., 8, 1205, 10.3389/fimmu.2017.01205 Veytia-Bucheli, 2018, Kv1.3 channel blockade with the Vm24 scorpion toxin attenuates the CD4+ effector memory T cell response to TCR stimulation, Cell Commun. Signal. : CCS, 16, 45, 10.1186/s12964-018-0257-7 Yuan, 2018, A Kv1.3 channel-specific blocker alleviates neurological impairment through inhibiting T-cell activation in experimental autoimmune encephalomyelitis, CNS Neurosci. Ther., 24, 967, 10.1111/cns.12848 Tanner, 2017, Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog, Clin. Immunol. (Orlando, Fla, 180, 45, 10.1016/j.clim.2017.03.014 Garcia-Calvo, 1993, Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels, J. Biol. Chem., 268, 18866, 10.1016/S0021-9258(17)46707-X Bednenko, 2018, A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3, mAbs, 10, 636, 10.1080/19420862.2018.1445451 Khodoun, 2020, Targeted knockdown of Kv1.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosus, Sci. Adv., 6, 10.1126/sciadv.abd1471 Grissmer, 1994, Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines, Mol. Pharmacol., 45, 1227 Varga, 2012, Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells, Mol. Pharmacol., 82, 372, 10.1124/mol.112.078006 Gurrola, 2012, Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes, Biochemistry, 51, 4049, 10.1021/bi300060n Beeton, 2011, Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases, Inflamm. Allergy - Drug Targets, 10, 313, 10.2174/187152811797200641 Teisseyre, 2019, Voltage-gated potassium channel Kv1.3 as a target in therapy of cancer, Front. Oncol., 9, 933, 10.3389/fonc.2019.00933 Castañeda, 1995, Characterization of a potassium channel toxin from the Caribbean Sea anemone Stichodactyla helianthus, Toxicon : Off. J. Int. Soc. Toxinol., 33, 603, 10.1016/0041-0101(95)00013-C Matheu, 2008, Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block, Immunity, 29, 602, 10.1016/j.immuni.2008.07.015 Kazama, 2016, Lymphocyte Kv1.3-channels in the pathogenesis of chronic obstructive pulmonary disease: novel therapeutic implications of targeting the channels by commonly used drugs, Allergy Asthma Clin. Immunol. : Off. J. Can. Soc. Allerg. Clin. Immunol., 12, 60, 10.1186/s13223-016-0168-3 Kazama, 2015, Roles of lymphocyte Kv1.3-channels in gut mucosal immune system: novel therapeutic implications for inflammatory bowel disease, Med. Hypotheses, 85, 61, 10.1016/j.mehy.2015.03.023 Rangaraju, 2015, Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease, J. Alzheim. Dis. : JAD, 44, 797, 10.3233/JAD-141704 Tajti, 2020, The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides, Biochem. Pharmacol., 114146, 10.1016/j.bcp.2020.114146